StockData
Polaryx Therapeutics, Inc. logo

Polaryx Therapeutics, Inc. (PLYX) stock

PLYXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 6/30
$1.60−0.07 (-4.19%)

Close on Nov 17, 2026Market cap $79.75MP/E –Yield –

Key statistics

Valuation at the latest close; fundamentals over fiscal , balances at Sep 30, 2026

Valuation

Market cap
$79.75M
P/E ratio
–
Price to sales
–
Price to book
10.48
Dividend yield
–
Free cash flow yield
–

Fundamentals

Net income
-$8.75M
EPS, diluted
-$0.18
Book value per share
$0.15
Diluted shares
50M

Trading

Previous close
$1.67
Open
$1.62
Day's range
$1.56 – $1.67
Volume
30,656
Average volume (20 days)
22,290
52-week range
$1.56 – $48.91
RSI (14 days)
34.5
Volatility (1 year)
186.6%
Relative volume
0.52×

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Nov 17, 2026. The S&P 500 is measured by the SPY fund.

PeriodPLYXS&P 500DifferencePLYX per yearS&P 500 per year
1 month-14.9%-4.0%−10.9 pts
3 months-23.8%-5.0%−18.8 pts

Three years at a glance

Fiscal years 2023 to 2025 and trailing twelve months, USD

Operating income

-$7.58M

Net income

-$8.75M

EPS, diluted

-$0.18
Reported periodTrailing twelve months

Press releases

Releases Polaryx Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K

About Polaryx Therapeutics

Pharmaceutical Preparations

Polaryx Therapeutics, Inc. is a clinical-stage biotechnology company that discovers and develops treatments for rare pediatric lysosomal storage disorders. Its therapeutic pipeline comprises oral small molecule candidates and gene therapies targeting underlying cellular dysfunction and neuroinflammation. The company's lead product candidate is PLX-200, a reformulated oral solution targeting neuronal ceroid lipofuscinosis subtypes CLN2 and CLN3, Krabbe disease, and Sandhoff disease. Other programs include PLX-300, a small molecule in preclinical evaluation, PLX-100, an oral combination therapy, and PLX-400, an early-stage gene therapy. The company operates in the lysosomal storage disorders segment, developing therapies primarily for pediatric patients diagnosed with fatal genetic metabolic conditions.

Company profile, executives and history

Polaryx Therapeutics stock: common questions

What is Polaryx Therapeutics's stock price?

PLYX closed at $1.60 on Nov 17, 2026, down 4.19% on the day. Over the past 52 weeks it traded between $1.56 and $48.91.

What is Polaryx Therapeutics's market cap?

Polaryx Therapeutics was worth $79.75M at the close on Nov 17, 2026: the share price times the diluted shares outstanding.

What is PLYX's P/E ratio?

Polaryx Therapeutics lost money over the twelve months to Sep 30, 2026 (diluted EPS -$0.18), so it has no meaningful P/E ratio.

Does Polaryx Therapeutics pay a dividend?

No. Polaryx Therapeutics has not paid a cash dividend over the last twelve months.

How many PLYX shares are sold short?

0M shares were sold short at the latest FINRA report, 0.59% of the float, or 6.5 days of average trading volume.

Who are Polaryx Therapeutics's competitors?

Companies most similar to Polaryx Therapeutics by business, industry and size include LRMR, GRCE, KTTA, AMLX, PRAX.

See a number that looks wrong?